Skip to main content
. 2021 Feb 23;39(12):1317–1328. doi: 10.1200/JCO.20.01366

FIG A2.

FIG A2.

Overall survival based on treatment group and age < 60 years (A) and ≥ 60 years (B) (ITT population). R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.